Patents by Inventor Roman Manetsch
Roman Manetsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11479532Abstract: Disclosed herein, are 5-Aminolevulinate synthase inhibitors and methods for their use in the treatment of porphyria.Type: GrantFiled: June 21, 2018Date of Patent: October 25, 2022Assignee: University of South FloridaInventors: Roman Manetsch, Gloria C. Ferreira, Bosko M. Stojanovski, Katya Pavlova Nacheva
-
Publication number: 20210269397Abstract: Disclosed herein, are 5-Aminolevulinate synthase inhibitors and methods for their use in the treatment of porphyria. In at least one specific embodiment, the 5-Aminolevulinate synthase inhibitors can include compounds or salts thereof of Formulas (I-V).Type: ApplicationFiled: June 21, 2018Publication date: September 2, 2021Applicant: University of South FloridaInventors: Roman MANETSCH, Gloria C. FERREIRA, Bosko M. STOJANOVSKI, Katya Pavlova NACHEVA
-
Patent number: 10551389Abstract: Methods of identifying target binding molecules by target guided synthesis are provided. The methods include providing two or more fragments capable of reacting to form the target binding molecule and mixing the fragments with the target. The methods can be used to identify target binding molecules that bind targets such as proteins or nucleic acids, including those that bind shallow binding pockets on the surface of such targets. The methods are applied to the Bcl-XL and Mcl-1 proteins from the Bcl-2 family of proteins. Using thio acid and sulfonyl azide fragments capable of reacting through sulfo-click chemistry, new acyl sulfonamides are identified that bind one or both of the Bcl-XL and Mcl-1 proteins. Pharmaceutical formulations of these target binding molecules are also provided.Type: GrantFiled: August 6, 2014Date of Patent: February 4, 2020Assignees: University of South Florida, The Penn State Research FoundationInventors: Roman Manetsch, Katya Pavlova Nacheva, David Lawrence Flanigan, Niranjan Kumar Namelikonda, Iredia David Iyamu, Sameer Shamrao Kulkarni, Megan M. Barber, Jeremiah Dwayne Tipton, Hong-Gang Wang, Kenichiro Doi
-
Patent number: 10323007Abstract: Described herein are quinazoline-based compounds and formulations thereof. In some embodiments, the compounds and/or formulations thereof can be effective to inhibit and/or kill A. baumannii. Also described herein are methods of treating a subject in need thereof by administering to the subject in need thereof a quinazoline-based compound and/or formulation thereof to the subject in need thereof.Type: GrantFiled: September 13, 2017Date of Patent: June 18, 2019Assignee: University of South FloridaInventors: Roman Manetsch, Kurt S. Van Horn, Whittney Burda, Lindsey N. Shaw, Renee Fleeman, Megan Barber, David Lawrence Flanigan
-
Publication number: 20190031613Abstract: Disclosed herein, in part, are compounds and methods for their use in the treatment of malaria.Type: ApplicationFiled: January 23, 2017Publication date: January 31, 2019Inventors: ROMAN MANETSCH, DENNIS E. KYLE, ANDRII MONASTYRSKYI, ALEXIS N. LACRUE, JORDANY R. MAIGNAN, FABIAN MARCEL BROCKMEYER
-
Patent number: 10081607Abstract: Embodiments of the present disclosure, in one aspect, relate to a 2,4-diaminoquinazoline compound, pharmaceutical compositions including a 2,4-diaminoquinazoline compound, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.Type: GrantFiled: October 31, 2014Date of Patent: September 25, 2018Assignee: University of South FloridaInventors: Roman Manetsch, Lindsey Neil Shaw, Kurt Steven Van Horn, Whittney Nicole Burda
-
Patent number: 10067136Abstract: Provided herein are pyridyl- and pyrimidyl-containing diazirines that can be photoactivateable probes and formulations thereof. Also provided herein are photoaffinity labels that can include the pyridyl- and pyrimidyl-containing diazirines provided herein. Also provided herein are methods of using the photoactivatable probes and photoaffinity labels provided herein in a photoaffinity labeling reaction and/or assay.Type: GrantFiled: February 6, 2017Date of Patent: September 4, 2018Assignee: University of South FloridaInventors: Roman Manetsch, Arun Babu Kumar, Jeremiah Tipton
-
Patent number: 10000452Abstract: Provided herein are quinolone-based compounds that can be used for treatment and/or prevention of malaria and formulations thereof. Also provided herein are methods of treating and/or preventing malaria in a subject by administering a quinolone-based compound or formulation thereof provided herein.Type: GrantFiled: January 23, 2017Date of Patent: June 19, 2018Assignees: University of South Florida, Northeastern UniversityInventors: Roman Manetsch, Dennis E. Kyle, Raghupathi Neelarapu, Jordany R. Maignan, Cynthia L. Lichorowic, Alexis N. LaCrue
-
Publication number: 20160116482Abstract: Methods of identifying target binding molecules by target guided synthesis are provided. The methods include providing two or more fragments capable of reacting to form the target binding molecule and mixing the fragments with the target. The methods can be used to identify target binding molecules that bind targets such as proteins or nucleic acids, including those that bind shallow binding pockets on the surface of such targets. The methods are applied to the Bcl-XL and Mcl-1 proteins from the Bcl-2 family of proteins. Using thio acid and sulfonyl azide fragments capable of reacting through sulfo-click chemistry, new acyl sulfonamides are identified that bind one or both of the Bcl-XL and Mcl-1 proteins. Pharmaceutical formulations of these target binding molecules are also provided.Type: ApplicationFiled: August 6, 2014Publication date: April 28, 2016Applicants: THE PENN STATE RESEARCH FOUNDATION, University of South FlordiaInventors: Roman Manetsch, Katya Pavlova Nacheva, David Lawrence Flanigan, Niranjan Kumar Namelikonda, Iredia David Iyamu, Sameer Shamrao Kulkarni, Megan M. Barber, Jeremiah Dwayne Tipton, Hong-Gang Wang, Kenichiro Doi
-
Patent number: 9206131Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: GrantFiled: October 16, 2013Date of Patent: December 8, 2015Assignees: Oregon Health & Science University, The Department of Veterans Affairs, Medicines for Malaria Venture, University of South FloridaInventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan
-
Publication number: 20150080409Abstract: Embodiments of the present disclosure, in one aspect, relate to a 2,4-diaminoquinazoline compound, pharmaceutical compositions including a 2,4-diaminoquinazoline compound, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.Type: ApplicationFiled: October 31, 2014Publication date: March 19, 2015Applicant: University of South Florida (A Florida Non-Profit Corporation)Inventors: Roman Manetsch, Lindsey Neil Shaw, Kurt Steven Van Horn, Whittney Nicole Burda
-
Patent number: 8906918Abstract: Embodiments of the present disclosure, in one aspect, relate to a 2,4-diaminoquinazoline compound, pharmaceutical compositions including a 2,4-diaminoquinazoline compound, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.Type: GrantFiled: March 22, 2013Date of Patent: December 9, 2014Assignee: University of South Florida (A Florida Non-Profit Corporation)Inventors: Roman Manetsch, Lindsey Neil Shaw, Kurt Steven Van Horn, Whittney Nicole Burda
-
Patent number: 8877752Abstract: Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of a Plasmodium infection in the recipient subject, or to reduce the likelihood of the onset or establishment of a Plasmodium infection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time.Type: GrantFiled: October 26, 2012Date of Patent: November 4, 2014Assignee: University of South FloridaInventors: Roman Manetsch, Richard Matthew Cross, Niranjan Kumar Namelikonda, Dennis Edward Kyle, Tina Susanna Mutka, Alexis Nichole LaCrue, Jordany Richarlson Maignan, Fabian Ernesto Saenz
-
Publication number: 20140045888Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: ApplicationFiled: October 16, 2013Publication date: February 13, 2014Applicants: Oregon Health & Science University, Medicines for Malaria Venture, University of South Florida, The Government of the United States of America dba The Department of Veterans AffairsInventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan
-
Patent number: 8598354Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: GrantFiled: June 3, 2011Date of Patent: December 3, 2013Assignees: University of South Florida, Medicines for Malaria VentureInventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan
-
Patent number: 8524947Abstract: The present disclosure relates to acylsulfonamides and processes for their preparation. The processes involve a target-guided synthesis approach, whereby a thioacid and a sulfonyl azide are reacted in the presence of a biological target protein, a Bcl-2 family protein, to form the acylsulfonamide.Type: GrantFiled: February 23, 2009Date of Patent: September 3, 2013Assignees: University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Hong-Gang Wang, Roman Manetsch, Xiangdong Hu, Sameer Kulkarni, Jiazhi Sun
-
Publication number: 20130203709Abstract: The present disclosure relates to acylsulfonamides and processes for their preparation. The processes involve a target-guided synthesis approach, whereby a thioacid and a sulfonyl azide are reacted in the presence of a biological target protein, a Bcl-2 family protein, to form the acylsulfonamide.Type: ApplicationFiled: August 9, 2011Publication date: August 8, 2013Applicants: THE PENN STATE RESEARCH FOUNDATION, UNIVERSITY OF SOUTH FLORIDAInventors: Roman Manetsch, Sameer Kulkarni, Iredia D. Iyamu, Hong-Gang Wang, Kenichiro Doi, Wayne Guida, Daniel Santiago, Courtney du Boulay
-
Publication number: 20130123258Abstract: Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of a Plasmodium infection in the recipient subject, or to reduce the likelihood of the onset or establishment of a Plasmodium infection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time.Type: ApplicationFiled: October 26, 2012Publication date: May 16, 2013Inventors: Roman Manetsch, Richard Matthew Cross, Niranjan Kumar Namelikonda, Dennis Edward Kyle, Tina Susanna Mutka, Alexis Nichole LaCrue, Jordany Richarlson Maignan, Fabian Ernesto Saenz
-
Publication number: 20120115904Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: ApplicationFiled: June 3, 2011Publication date: May 10, 2012Inventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan
-
Publication number: 20120077869Abstract: Phosphotyrosine phosphatase (PTP) encoded by PF13_0027 is a desirable drug target for the human malaria parasite Plasmodium falciparum. This PTP is critical for intraerythrocytic parasite development and invasion of erythrocytes by malaria merozoites. Mutation of the PF13_0027 gene or blocking expression of PTP function to create a PTP-null parasite severely attenuates the malaria parasite's ability to survive, making the PTP-null parasite suitable as an attenuated blood-stage parasite vaccine.Type: ApplicationFiled: September 20, 2011Publication date: March 29, 2012Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: John H. Adams, Bharath Balu, Steven P. Maher, Christopher O. Campbell, Roman Manetsch